Skip to main content

DaVita plays down Ozempic’s potential in treating kidney disease

Dialysis company DaVita is not convinced a Novo Nordisk trial's findings relating to its Ozempic treatment will be borne out over time.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.